Special focus section: Gene therapy for Parkinson's disease

Experimental Neurology

Volumn 209, Issue 1, 2008, Pages 28-29

  Fiske, Brian K ^a   Frasier, Mark A ^a   Sherer, Todd B ^a  

^a THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; VIRUS VECTOR;

BASAL GANGLION; BLOOD BRAIN BARRIER; BRADYKINESIA; CELL BASED GENE THERAPY; CELL ENCAPSULATION; CLINICAL FEATURE; DISEASE COURSE; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GENE EXPRESSION; GENE TECHNOLOGY; GENE THERAPY; HUMAN; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; TRANSGENE; TREMOR; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DRUG APPROVAL; GENE THERAPY; HUMANS; PARKINSON DISEASE; UNITED STATES;

EID: 37549013793     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.09.006     Document Type: Editorial

References (10)

1. Cress D.E. The need for regulatable vectors for gene therapy for Parkinson's disease. Exp. Neurol. 209 (2008) 30-33
2. Fiandaca M.S., Forsayeth J., and Bankiewicz K. Current status of gene therapy trials for Parkinson's disease. Exp. Neurol. 209 (2008) 51-57
3. Havert M. A regulatory perspective on the development of gene therapy for Parkinson's disease. Exp. Neurol. 209 (2008) 48-50
4. Kordower J.H., and Olanow C.W. Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself?. Exp. Neurol. 209 (2008) 34-40
5. Lewis T., and Standaert D. Design of clinical trials of gene therapy in Parkinson's disease. Exp. Neurol. 209 (2008) 41-47
6. Lindvall O., and Wahlberg L. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?. Exp. Neurol. 209 (2008) 82-88
7. Maguire-Zeiss K., Mhyre T., and Federoff H. Gazing into the future: Parkinson's disease gene therapeutics to modify natural history. Exp. Neurol. 209 (2008) 101-113
8. Mandel R.J., Burger C., and Snyder R.O. Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production. Exp. Neurol. 209 (2008) 58-71
9. Porras G., and Bezard E. Preclinical development of gene therapy for Parkinson's disease. Exp. Neurol. 209 (2008) 72-81
10. Ulusoy A., Bjorklund T., Hermening S., and Kirik D. In vivo gene delivery for development of mammalian models for Parkinson's disease. Exp. Neurol. 209 (2008) 89-100